Antibody-Drug Conjugate Therapy for Cancer Treatment

Chari, Ravi V.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Small Business Innovation Research Grants (SBIR) - Phase II (R44)
• Project #: 5R44CA056209-03
• Application #: 2683518
• Study Section: Special Emphasis Panel (ZRG2-SSS-4 (02))
• Program Officer: Muszynski, Karen
• Project Start: 1992-07-01
• Project End: 1999-09-30
• Budget Start: 1998-04-15
• Budget End: 1999-09-30
• Support Year: 3
• Fiscal Year: 1998

Institution

• Name: Immunogen, Inc.
• City: Cambridge
• State: MA
• Country: United States
• Zip Code: 02139

Publications

Xie, Hongsheng; Audette, Charlene; Hoffee, Mary et al. (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther 308:1073-82